ZHU Tao

  • Professor of School of Life Sciences

    University of Science & Technology of China

     

    Tel: 86-551-63601505

    Fax:86-551-63601505

    e-mail: zhut@ustc.edu.cn

    Hmepage:

    Personal Profile

    I acquired the M.D. from Wuhan University School of Medicine in 1994 and Ph.D. from the Institute of Molecular and Cell Biology (IMCB) at Singapore in 2002. Between 2003 and 2007, I received my postdoctoral training in IMCB and Johns Hopkins University School of Medicine. I am the co-author of 40 plus scientific publications mostly in peer-reviewed international journals including PNAS, Cancer Res., J. Biol. Chem. and Oncogene. Those publications have been cited more than 1,000 times and H index=16.

    Research Interests

    We are a laboratory in tumor pathology study. Currently, we are focusing on elucidation of 1) The mechanisms of growth factors involved in endocrine related cancers; 2) Pathological characterization of noncoding RNA in cancer; 3) Novel therapeutic approaches for cancer treatment.

    Selected Publications

    1.Xuefei Lu, Ying Liu, and Lobie PE, Chunying Chen*, Zhu T*. (2013) Nanotoxicity: the growing need for study in the endocrine system. SMALL, DOI: 10.1002/smll. 20120151

    2.Qian PX, Banerjee A, Wu ZS, Zhang X, Wang H, Pandey V, Zhang WJ, Lv XF, Tan S, Lobie PE*, and Zhu T*. (2012) Loss of SNAIL regulated miR-128-2 on chromosome 3p22.3 promotes mammary epithelial cell oncogenic transformation via targeting multiple stem cell factors. Cancer Res. 72,6036-6050.

    3.Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi A, Landberg G, Bieche I, Lobie PE, Davidson NE , Zaver M. Bhujwalla ZM, Zhu T*, Sukumar S*. (2012) HOXB7 renders breast cancer resistant to tamoxifen through activation of the EGFR Pathway. PNAS 109,2736-41.

    4.Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, Wu Z, Chen T, Wu W, Lobie PE* and Zhu T*(2012) MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression.PLoS ONE  7,e41523

    5. Banerjee A, Wu ZS, Qian PX, Kang J, Liu DX,  Zhu T* and Lobie PE*. (2012) ARTEMIN promotes de novo angiogenesis in ER negative 1mammary carcinoma through activation of TWIST1-VEGF-A signalling. PLoS ONE  7, e50098

    6.Banerjee A, Qian P, Wu ZS, Ren X, Steiner M, Bougen NM, Liu DX, Zhu T*, and Lobie PE*. (2012) ARTEMIN stimulates chemo and radio- -resistance by promoting TWIST1-BCL-2 dependent cancer stem cell-like behaviour in ER negative mammary carcinoma cells. J Biol Chem. 287,42502-15

    7.Qian P, Zuo Z, Wu Z, Meng X, Li G, Wu Z, Zhang W, Tan S, Pandey V, Yao Y, Wang P, Zhao L, Wang J, Wu Q, Song E, Lobie PE, Yin Z*, Zhu T*. (2011) Pivotal Role of Reduced let-7g Expression in Breast Cancer Invasion and Metastasis. Cancer Res.71,6463-6474.

    8.Wu ZS, Yang K, Wan Y, Qian PX, Perry JK, Mertani HC, Zhu T*, Lobie P*. (2011) Tumor expression of hGH and hPRL predict a worse survival outcome in patients with mammary and endometrial carcinoma.J Clin Endocrinol Metab. 96, E1619-1629.

    9.Banerjee A, Wu ZS, Qian PX, Kang J, Pandey V, Liu DX,Zhu T*, Lobie PE* (2011) Twist1 mediates artemin stimulated metastasis of ER- mammary carcinoma. Breast Cancer Res. 13,R112.

    10.Pandey V, Qian PX, Kang J, Perry JK, Mitchell MD, Yin ZN, Wu ZS, Liu DX, Zhu T*, Lobie PE*. (2010) Artemin stimulates oncogenicity and invasion of endometrial carcinoma cells. Endocrinology 151,909-920.